{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:08:07Z","timestamp":1761901687712,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.msard.2020.102356","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T21:29:29Z","timestamp":1593725369000},"page":"102356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Posterior Reversible Encephalopathy Syndrome, Multiple Sclerosis and interferon therapy: Association, co-incidence or convoluted interplay?"],"prefix":"10.1016","volume":"45","author":[{"given":"Vasileios C.","family":"Mastorodemos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanos G.","family":"Ioannidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efrosini Z.","family":"Papadaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayiotis D.","family":"Mitsias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.msard.2020.102356_bib0001","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestaions, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.msard.2020.102356_bib0002","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.1007\/s12035-019-1553-y","article-title":"Arginine vasopressin and posterior reversible encephalopathy syndrome pathophysiology: the missing link?","volume":"56","author":"Largeau","year":"2019","journal-title":"Mol Neurobiol."},{"key":"10.1016\/j.msard.2020.102356_bib0003","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.msard.2013.12.007","article-title":"Thrombotic microangiopathy in interferon beta treated multiple sclerosis paients: review of literature and report of two new cases","volume":"3","author":"Vsoughi","year":"2014","journal-title":"Mult Scler Relat Disord."},{"issue":"11","key":"10.1016\/j.msard.2020.102356_bib0004","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1177\/1352458515618020","article-title":"Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients","volume":"22","author":"Fok","year":"2016","journal-title":"Mult Scler."},{"issue":"24","key":"10.1016\/j.msard.2020.102356_bib0005","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.msard.2020.102356_bib0006","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1177\/1352458512441272","article-title":"Arterial hypertension induced by interferon beta 1b in a patient with multiple sclerosis","volume":"18","author":"Modrego","year":"2012","journal-title":"Mult Scler."},{"key":"10.1016\/j.msard.2020.102356_bib0007","article-title":"Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse","volume":"2015","author":"Morrow","year":"2015","journal-title":"Case Rep Neurol Med."},{"key":"10.1016\/j.msard.2020.102356_bib0008","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fneur.2015.00039","article-title":"A case of posterior reversible encephalopathy syndrome associated with GilenyaR(fingolimod) treatment for multiple sclerosis","volume":"6","author":"Linda","year":"2015","journal-title":"Front Neurol."},{"key":"10.1016\/j.msard.2020.102356_bib0009","unstructured":"Novartis Data on File [Fingolimod Periodic Safety Update Report, 2019. Period covered: 01 Mar 2018 -28 Feb 2019. Release date: 24-Apr-2019]."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:51:53Z","timestamp":1761900713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820304314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":9,"alternative-id":["S2211034820304314"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102356","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posterior Reversible Encephalopathy Syndrome, Multiple Sclerosis and interferon therapy: Association, co-incidence or convoluted interplay?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102356"}}